



Integrins and Tumor Microenvironment, New Perspectives in Targeted Treatments

Guest Editors:

Dr. Francesca Bianchini

Experimental Pathology and
Oncology Section of the
Department of Experimental and
Clinical Biomedical Sciences,
University of Florence, Viale GB
Morgagni 50, 50134 Firenze, Italy

Dr. Andrea Trabocchi

Department of Chemistry “Ugo
Schiff”, University of Florence,
50019 Sesto Fiorentino, Italy

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Integrins are a family of cell surface receptors with a longstanding history in cancer. The integrin-mediated binding of extracellular matrix components (ECM) by cancer cells leads to essential signaling for cancer cell survival, proliferation, migration, extravasation, and metastatic dissemination to secondary organs.

Indeed, integrins are expressed not only on cancer cells, but also on stromal cells, such as endothelial cells and cancer-associated fibroblasts (CAFs), and on host immune cells, such as tumor-associated macrophages (TAMs) and tumor-infiltrating lymphocytes (TILs).

Thus, the aim of this issue is to unravel the role of integrins in cancer–TME crosstalk, exploring novel molecular pathways by which integrins might promote cancer progression and resistance to anticancer therapy, and suggesting innovative targets for therapeutic interventions.

We solicit contributions on all topics connected to this area, including, but not limited to:

- Integrins in cancer cell – TME interactions driving drug resistance
- Integrins in cancer immune evasion strategies
- Development of antibody/small-molecule–drug conjugates
- Integrins as tools for molecular imaging





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)